Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants

Drugs of Today

Volumn 43, Issue 8, 2007, Pages 569-581

  Lee, Min Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEBRISOQUINE; FLUOXETINE; FLUVOXAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROTRANSMITTER; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN 2A AGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN HYDROXYLASE; VENLAFAXINE;

BIPOLAR DEPRESSION; CLINICAL FEATURE; DEPRESSION; DIZZINESS; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; GENE FUNCTION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HUMAN; MAJOR DEPRESSION; NAUSEA; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PROTEIN BLOOD LEVEL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER, MAJOR; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRYPTOPHAN HYDROXYLASE;

EID: 34948869889     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.8.1130447     Document Type: Review

References (111)

1. Bertz, R.J., Granneman, G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997, 32: 210-58.
2. Evans, W.E., Relling, M.V. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999, 286: 487-91.
3. Bondy, B., Zill, P. Pharmacokinetics and psychopharmacology. Curr Opin Pharmacol 2004, 4: 72-8.
4. Smeraldi, E., Zanardi, R., Benedetti, F., Di Bella, D., Perez, J., Catalano, M. Polymorphism within the promoter of the serotonin transporter gene and antidepressants efficacy of fluvoxamine. Mol Psychiatry 1998, 3: 508-11.
5. Pollock, B.G., Ferrell, R.E., Mulsant, B.H., Mazumdar, S., Miller, M., Sweet, R.A. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000, 23: 587-90.
6. Zanardi, R., Benedetti, F., Di Bella, D., Catalano, M., Smeraldi, E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000, 20: 105-7.
7. Kim, D.K., Lim, S.W., Lee, S., Sohn, S.E., Kim, S., Hahn, C.G. Serotonin transporter gene polymorphism and antidepressants response. Neuroreport 2000, 11: 215-9.
8. Arias, B., Catalan, R., Gasto, C., Gutierrez, B., Fananas, L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with Citalopram in a 12-week follow-up study. J Clin Psychopharmacol 2003, 23: 563-7.
9. Rausch, J.L., Johnson, M.E., Fei, Y.J., Li, J.Q., Shendarkar, N., Hobby, H.M. Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biol Psychiatry 2002, 51: 723-32.
10. Yu, Y.W., Tsai, S.J., Chen, T.J., Lin, C.H., Hong, C.J. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressants response in major depressive disorders. Mol Psychiatry 2002, 7: 1115-9.
11. Yoshida, K., Ito, K., Sato, K., Takahashi, H., Kamata, M., Higuchi, H. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressants response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002a, 26: 383-6.
12. Durham, L.K., Webb, S.M., Milos, P.M., Clary, C.M., Seymour, A.B. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004, 174: 525-9.
13. Serretti, A., Cusin, C, Rossini, D. et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2004, 129: 36-40.
14. Lee, M.S., Lee, H.Y., Lee, H.J., Ryu, S.H. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressants treatment. Psychiatric Genetics 2004, 14: 111-5.
15. Kato, M., Fukuda, T., Wakeno, M. et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006, 53: 186-9.
16. Choi, M.J., Kang, R.H., Ham, B.J., Jeong, H.Y., Lee, M.S. Serotonin receptor 2A gene Polymorphism (-1438A/G) and short-term treatment response to citalopram Neuropsychobiology 2005, 52: 155-62.
17. Cusin, C., Serretti, A., Zanardi, R. et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol 2002, 5: 27-35.
18. Sato, K., Yoshida, K., Takahashi, H. et al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002, 46: 136-40.
19. Minov, C., Baghai, T.C., Schule, C. et al. Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression. Neurosci Lett 2001, 303: 119-22.
20. Wu, W.H., Huo, S.J., Cheng, C.Y., Hong, C.J., Tsai, S.J. Association study of the 5-HT (6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 2001, 44: 172-5.
21. Lee, S.H., Lee, K.J., Lee, H.J., Ham, B.J., Ryu, S.H., Lee, M.S. Association between the 5-HT6 receptor C267T polymorphism and response to antidepressants treatment in major depressive disorder. Psychiatr Clin Neurosci 2005, 59: 140-5.
22. Ham, B.J., Lee, B.C., Paik, J.W. et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31: 104-7.
23. Yoshida, K., Naito, S., Takahashi, H., Sato, K., Ito, K., Kamata, M. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressants response to fluvoxamine in Japanese patients with major depressive disorder. Pro Neuropsychopharmacol Biol Psychiatry 2002b, 26: 1279-83.
24. Serretti, A., Zanardi, R., Cusin, C., Rossini, D., Lorenzi, C., Smeraldi, E. Tryptophan hydroxylase gene associated with paroxetine antidepressants activity. Eur Neuropsychopharmacol 2001a, 11: 375-80.
25. Serretti, A., Zanardi, R., Rossini, D., Cusin, C, Lilli, R., Smeraldi, E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressants activity. Mol Psychiatry 2001b, 6: 586-92.
26. Serretti, A., Lorenzi, C., Cusin, C., Zanardi, R., Lattuada, E., Rossini, D. SSRIs antidepressants activity is influenced by Gbeta3 variants. Eur Neuropsychopharmacol 2003, 13: 117-22.
27. Zill, P., Baghai, T.C., Zwanzger, P., Schule, C., Minov, C., Riedel, M. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressants treatment. Neuroreport 2000, 11: 1893-7.
28. Yoshida, K., Higuchi, H., Kamata, M. et al. G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol 2006 (Epub ahead of print).
29. Choi, M.J., Kang, R.H., Lim, S.W. et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 2006, 1118: 176-82.
30. Tsai, S.J., Cheng, CY, Yu, Y.W., Chen, T.J., Hong, C.J. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet 2003, 123B: 9-22.
31. Ramamoorthy, S., Bauman, A.L., Moore, K.R., Han, H., Yang-Feng, T., Chang, A.S. Antidepressants- and cocaine-sensitive human serotonin transporter molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 1993, 90: 2542-6.
32. Lesch, K.P., Balling, U., Gross, J. et al. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 1994, 95: 157-62.
33. Heils, A., Teufel, A., Petri, S., Stober, G., Riederer, P., Bengel, D. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996, 66: 2621-4.
34. Montgomery, S.A. Long-term treatment of depression. Br J Psychiatry 1994, 26 (Suppl.): 31-6.
35. Smeraldi, E., Benedetti, F., Zanardi, R. Serotonin transporter promoter genotype and illness recurrence in mood disorders. Eur Neuropsychopharmacol 2002, 12: 73-5.
36. Kunugi, H., Hattori, M., Kato, T., Tatsumi, M., Sakai, T., Sasaki, T. Serotonin transporter gene polymorphisms: Ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997, 2: 457-62.
37. Ham, B.J., Lee, M.S., Lee, H.J. et al. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressants response in a Korean population. Psychiatric Genetics 2005, 15: 299-301.
38. Burnet, P.W., Eastwood, S.L., Lacey, K., Harrison, P.J. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res 1995, 675: 157-68.
39. Glennon, R.A., Dukat, M. Serotonin receptor subtypes. In: Bloom, F.E., Kupfer, D.J. (Eds.). Editors, Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York 1995, 45: 1125-31.
40. Maj, J., Bijak, M., Dziedzicka-Wasylewska, M. et al. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology (Berl) 1996, 127:73-82.
41. Yatham, L.N., Liddle, P.F., Dennie, J. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: A positron emission tomography study with fluorine-18-labled setoperone. Arch Gen Psychiatry 1999, 56: 705-11.
42. Chen, K., Yang, W., Grimsby, J., Shih, J.C. The human 5-HT2A receptor is encoded by a Multiple intron exon gene. Brain Res Mol Brain Res 1992, 14: 20-6.
43. 2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia. Human Genetics 1996, 97: 614-9.
44. Arranz, M.J., Munro, J., Owen, M.J. et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998, 3: 61-6.
45. Spurlock, G., Helis, A., Holmas, P., Williams, J., Dsouza, U.M., Cardno, A. A family-based asociation study of T 102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 1998, 3: 42-9.
46. Monsma, F.J. Jr, Shen, Y., Ward, R.P., Hamblin, M.W., Sibley, D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993, 3: 320-7.
47. Ward, R.P., Hamblin, M.W., Lachowicz, J.E., Hoffman, B.J., Sibley, D.R., Dorsa, D.M. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neurosci 1995, 64: 1105-11.
48. Sleight, A.J., Boess, F.G., Bos, M., Bourson, A. The putative 5-ht6 receptor: Localization and function. Ann NY Acad Sci 1998, 861: 91-6.
49. Yoshioka, M., Matsumoto, M., Togashi, H., Mori, K. Central distribution and function of 5-HT6 receptor subtype in the rat brain. Ann NY Acad Sci 1998, 861:244.
50. Roth, B.L., Craigo, S.C., Choudhary, M.S. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994, 268: 1403-10.
51. Kohen, R., Metcalf, M.A., Khan, N. Cloning, characterization and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996, 66: 47-56.
52. Vogt, I.R., Shimron-Abarbanell, D., Neidt, H. Investigation of the human serotonin 6 (5HT6) receptor gene in bipolar affective disorder and schizophrenia. Am J Med Genet 2000, 96: 217-21.
53. Pickar, D., Rubinow, K. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci 2001, 22: 75-83.
54. Boularand, S., Darmon, M.C., Ganem, Y., Launay, J.M., Mallet, J. Complete coding sequence of human tryptophan hydroxylase. Nucleic Acids Res 1990, 18: 4257.
55. Craig, S.P., Boularand, S., Darmon, M.C., Mallet, J., Craig, I.W. Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3-p14 by in situ hybridization. Cytogenet Cell Genet 1991, 56: 157-9.
56. Nielsen, D.A., Jenkins, G.L., Stefanisko, K.M., Jefferson, K.K., Goldman, D. Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Brain Res Mol Brain Res 1997, 45: 145-8.
57. Birnbaumer, W., Abramowitz, J., Brown, A.M. Receptor-effector coupling by G protein. Biochim Biophys Acta 1990, 103: 163-224.
58. Gilman, A.G. G protein: Transducers of receptor-generated signals. Annu Rev Biochem 1987, 56: 615-49.
59. Ford, C.E., Skiba, N.P., Bae, H., Daaka, Y., Reuveny, E., Shekter, L.R. Molecular basis for interactions of G protein beta-gamma subunits with effectors. Science 1998, 280: 1271-4.
60. Hamm, H.E. The many faces of G protein signaling. J Biol Chem 1998, 273: 669-72.
61. Siffert, W., Rosskopf, D., Siffert, G., Busch, S., Moritz, A., Erbel, R. Association of a human G protein beta3 subunit variant with hypertension. Nat Genet 1998, 18: 45-8.
62. Benjafield, A.V., Jeyasingam, C.L., Nyholt, D.R., Griffiths, L.R., Morris, B.J. G protein betas subunit gene (GNB3) variant in causation of essential hypertension. Hypertension 1998, 32: 1094-7.
63. Dong, Y., Zhu, H., Sagnella, G.A., Carter, N.D., Cook, D.G., Cappuccio, F.P. Association between the C825T polymorphism of the G protein beta3-subunit gene and hypertension in blacks. Hypertension 1999, 34: 1193-6.
64. Hengstenberg, C., Schunkert, H., Mayer, B., Doring, A., Lowel, H., Hense, H.W. Association between a polymorphism in the G protein beta3subunit gene (GNB3) with arterial hypertension but not with myocardial infarction. Cardiovasc Res 2001, 49: 820-7.
65. Hegele, R.A., Anderson, C., Young, T.K., Connelly, P.W. G-protein beta3 subunit gene splice variant and body fat distribution in Nunavut Inuit. Genome Res 1999, 9: 972-7.
66. Virchow, S., Ansorge, N., Rosskopf, D., Rubben, H., Siffert, W. The G protein beta3 subunit splice variant Gbeta3-s causes enhanced chemotaxis of human neutrophils in response to interleukin-8. Naunyn-Schmiedeberg's Arch Pharmacol 1999, 360: 27-32.
67. Rosskopf, D., Koch, K., Habich, C., Geerdes, J., Ludwig, A., Wilhelms, S. Interaction of Gbeta3s, a splice variant of the G-protein Gbeta3, with Ggamma- and Galpha-proteins. Cell Signal 2003, 15: 479-88.
68. Jones, K.R., Reichardt, L.F. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc Natl Acad Sci USA 1990, 87: 8060-4.
69. Leibrock, J., Lottspeich, F., Hohn, A. et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 1989, 341: 149-52.
70. Ventimiglia, R., Mather, P.E., Jones, B.E., Lindsay, R.M. The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 1995, 7: 213-22.
71. Altar, C.A. Neurotrophins and depression. Trends Pharmacol Sci 1999, 20: 59-61.
72. Coyle, J.T., Duman, D.S. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003, 38: 157-60.
73. Duman, R.S. Synaptic plasticity and mood disorders. Mol Psychiatry 2002, 7: S29-34.
74. Duman, R.S., Henninger, G.R., Nestler, E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54: 597-606.
75. Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., Monteggia, L.M. Neurobiology of depression. Neuron 2002, 34: 13-25.
76. Nestler, E.J., Gould, E., Manji, H. et al. Preclinical models: Status of basic research in depression. Biol Psychiatry 2002, 52: 503-28.
77. Duman, R.S., Charney, D.S. Cell atrophy and loss in major depression. Biol Psychiatry 1999, 45: 1083-4.
78. Watanabe, Y., Gould, E., McEwen, B.S. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res 1992, 588: 341-5.
79. Smith, M.A., Makino, S., Kvetnansky, R., Post, R.M. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995, 15: 1768-77.
80. Shimizu, E., Hashimoto, K., Okamura, N. et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Bio Psychiatry 2003, 54: 70-5.
81. Chen, B., Downlatshahi, D., Macqueen, G.M., Wang, J.E., Young, L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001, 50: 260-5.
82. Maisonpierre, P.C., Le Beau, M.M., Espinosa, R. III et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: Gene structures, distributions and chromosomal localizations. Genomics 1991, 10: 558-68.
83. Ozcelik, T., Rosenthal, A., Franke, U. Chromosomal mapping of brain-derived neurotrophic factor and neurotrophin-3 genes in man and mouse. Genomics 1994, 10: 569-75.
84. Mowla, S.J., Farhadi, H.F., Pareek, S. et al. Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem 2001, 276: 12660-6.
85. Proschel, M., Saunders, A., Roses, A.D., Müller, CR. Dinucleotide repeat polymorphisms at the human gene for brain-derived neurotrophic factor (BDNF). Hum Mol Genet 1992, 1: 353.
86. Hall, D., Dhilla, A., Charalambous, A., Gogos, J.A., Karayiorgou, M. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet 2003, 73: 370-6.
87. Neves-Pereira, M., Mundo, E., Muglia, P., King, N., Macciardi, F., Kennedy, J.L. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: Evidence from a family-based association study. Am J Hum Genet 2002, 71: 651-5.
88. Geller, B., Badner, J.A., Tillman, R., Christian, S.L., Bolhofner, K., Cook, E.H. Jr. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry 2004, 161: 1698-700.
89. Sen, S., Nesse, R.M., Stoltenberg, S.F., Li, S., Gleiberman, L., Chakravarti, A. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003, 28: 397-401.
90. Sklar, P., Gabriel, S.B., McInnis, M.G., Bennett, P., Lim, Y.M., Tsan, G. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry 2002, 7: 579-93.
91. Bertilsson, L. Geographical/interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics 1995, 29: 192-209.
92. Lin, K.M., Poland, R.E., Wan, Y.J.Y., Smith, M.W., Lesser, I.M. The evolving science of pharmacogenetics: Clinical and ethnic perspectives. Psychopharmacol Bull 1996, 32: 205-17.
93. Meyer, U.A. Pharmacogenetics: The slow, the rapid, and the ultrarapid. Pro Natl Acad Sci USA. 1994, 91: 1983-4.
94. Hamelin, B.A., Turgeon, J., Vallee, F., Belanger, P.M., Paquet, F., Lebel, M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996, 60: 512-21.
95. Wang, J.H., Liu, Z.Q., Wang, W., Chen, X.P., Shu, Y., He, N. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001, 70: 42-7.
96. Guttendorf, R.J., Wedlund, P.J. Genetic aspects of drug disposition and therapeutics. J Clin Pharmacol 1992, 32: 107-17.
97. Bertilsson, L., Lou, Y.Q., Du, Y.L. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992, 51: 338-97.
98. Johansson, I., Oscarson, M., Yue, Q.Y., Bertilsson, L., Sjoqvist, F., Ingelman-Sundberg, M. Genetic analysis of the Chinese cytochrome P-4502D locus: Characterization of variant CYP2D6 gene present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994, 46: 452-9.
99. Nakamura, K., Goto, F., Ray, W.A. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985, 10: 402-8.
100. Roh, H.K., Dahl, M.L., Johansson, I. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996, 6: 441-7.
101. Lou, Y.C. Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metab Rev 1990, 22: 451-75.
102. Daniel, H.I., Edeki, T.I. Genetic polymorphism of S-mephenytoin 4′-hydroxylation Psychopharmacol Bull 1996, 32: 219-30.
103. Rettie, A.E., Wienkers, L.C., Gonzalez, F.J., Trager, W.F., Korzekwa, K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994, 4: 39-42.
104. Sullivan-Klose, T.H., Ghanayem, B.I., Bell, D.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996, 6: 341-9.
105. Scordo, M.G., Aklillu, E., Yasar, U., Dahl, M.L., Spina, E., Ingelman-Sundberg, M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001, 52: 447-50.
106. Scordo, M.G., Spina, E., Dahl, M.L., Gatti, G., Perucca, E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005, 97: 296-301.
107. Meyer, U.A., Zanger, U.M., Grant, D. Genetic polymorphisms of drug metabolism. Adv Drug Res 1990, 19: 197-241
108. Inaba, T., Nebert, D.W., Burchell, B. Pharmacokinetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 1995, 73: 331-8.
109. Kalow, W., Bertilsson, L. Interethnic factors affecting drug response. Adv Drug Res 1994, 25: 1-53.
110. de Morais, S.M., Wilkinson, G.R., Blaisdell, J. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994, 269: 15419-22.
111. Goldstein, J.A., Ishizaki, T., Chiba, K. Frequencies of defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997, 7: 59-64.